JIANGSU BIOPERFECTUS TECHNOLOGIES CO., LTD. Financials Jiangsu Bioperfectus Technologies Co., Ltd.
Equities
688399
CNE1000055B2
Medical Equipment, Supplies & Distribution
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 75.06 CNY | +0.27% |
|
+2.21% | +37.57% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Capitalization 1 | 3,394 | 11,275 | 8,060 | 5,142 | 3,198 |
| Enterprise Value (EV) 1 | 2,565 | 9,890 | 6,314 | 2,438 | 907.6 |
| P/E ratio | 31.3 x | 13.8 x | 6.76 x | 2.81 x | -8.55 x |
| Yield | 2.59% | 3.64% | 7.27% | - | - |
| Capitalization / Revenue | 11.8 x | 6.48 x | 2.84 x | 0.93 x | 7.93 x |
| EV / Revenue | 8.88 x | 5.68 x | 2.22 x | 0.44 x | 2.25 x |
| EV / EBITDA | 25.5 x | 10.6 x | 4.7 x | 1.08 x | -6.23 x |
| EV / FCF | -187 x | 17.8 x | 12.5 x | 2.48 x | -7.67 x |
| FCF Yield | -0.54% | 5.63% | 8.02% | 40.3% | -13% |
| Price to Book | 3.32 x | 6.77 x | 3.18 x | 1.36 x | 0.94 x |
| Nbr of stocks (in thousands) | 58,620 | 58,620 | 58,620 | 58,620 | 58,620 |
| Reference price 2 | 57.90 | 192.3 | 137.5 | 87.71 | 54.56 |
| Announcement Date | 4/23/20 | 3/25/21 | 4/14/22 | 4/26/23 | 4/26/24 |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 230.7 | 288.8 | 1,740 | 2,839 | 5,535 | 403.2 |
| EBITDA 1 | 72.67 | 100.6 | 932.9 | 1,344 | 2,255 | -145.7 |
| EBIT 1 | 59.25 | 83.36 | 911 | 1,311 | 2,173 | -214.5 |
| Operating Margin | 25.68% | 28.86% | 52.36% | 46.16% | 39.26% | -53.2% |
| Earnings before Tax (EBT) 1 | 72.97 | 94.7 | 961 | 1,392 | 2,139 | -375.7 |
| Net income 1 | 63.82 | 83.76 | 819.6 | 1,193 | 1,828 | -373.8 |
| Net margin | 27.67% | 29% | 47.11% | 42.03% | 33.03% | -92.72% |
| EPS 2 | 1.450 | 1.850 | 13.98 | 20.36 | 31.18 | -6.380 |
| Free Cash Flow 1 | -46.06 | -13.75 | 556.3 | 506.2 | 981.9 | -118.4 |
| FCF margin | -19.96% | -4.76% | 31.98% | 17.83% | 17.74% | -29.36% |
| FCF Conversion (EBITDA) | - | - | 59.64% | 37.67% | 43.55% | - |
| FCF Conversion (Net income) | - | - | 67.88% | 42.42% | 53.72% | - |
| Dividend per Share | - | 1.500 | 7.000 | 10.00 | - | - |
| Announcement Date | 11/14/19 | 4/23/20 | 3/25/21 | 4/14/22 | 4/26/23 | 4/26/24 |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 212 | 829 | 1,385 | 1,747 | 2,703 | 2,291 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -46.1 | -13.7 | 556 | 506 | 982 | -118 |
| ROE (net income / shareholders' equity) | 21.8% | 12.5% | 61% | 56.8% | 57.9% | -10.4% |
| ROA (Net income/ Total Assets) | 10.5% | 6.72% | 33.2% | 28.4% | 32.4% | -3.05% |
| Assets 1 | 608.6 | 1,246 | 2,470 | 4,208 | 5,647 | 12,265 |
| Book Value Per Share 2 | 7.370 | 17.40 | 28.40 | 43.30 | 64.50 | 58.10 |
| Cash Flow per Share 2 | 4.830 | 4.240 | 19.40 | 22.00 | 30.60 | 30.20 |
| Capex 1 | 98.7 | 106 | 135 | 304 | 351 | 111 |
| Capex / Sales | 42.8% | 36.63% | 7.73% | 10.69% | 6.34% | 27.62% |
| Announcement Date | 11/14/19 | 4/23/20 | 3/25/21 | 4/14/22 | 4/26/23 | 4/26/24 |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +37.57% | 608M | |
| -1.49% | 12.71B | |
| +0.13% | 8.37B | |
| -1.12% | 5.4B | |
| +20.18% | 5.27B | |
| -0.74% | 4.63B | |
| -54.68% | 3.13B | |
| +24.56% | 2.77B | |
| -8.47% | 2.25B | |
| -1.86% | 1.95B |
- Stock Market
- Equities
- 688399 Stock
- Financials Jiangsu Bioperfectus Technologies Co., Ltd.